Daniel Sidler, Alexander Born, Simeon Schietzel, Michael P Horn, Daniel Aeberli, Jennifer Amsler, Burkhard Möller, Linet M Njue, Cesare Medri, Anne Angelillo-Scherrer, Luca Borradori, S Morteza Seyed Jafari, Susanne Radonjic-Hoesli, Andrew Chan, Robert Hoepner, Ulrike Bacher, Laila-Yasmin Mani, Joseena Mariam Iype, Franziska Suter-Riniker, Cornelia Staehelin, Michael Nagler, Cedric Hirzel, Britta Maurer, Matthias B Moor
BACKGROUND: The majority of patients with B-cell-depleting therapies show compromised vaccination-induced immune responses. Herein, we report on the trajectories of anti-SARS-CoV-2 immune responses in patients of the RituxiVac study compared with healthy volunteers and investigate the immunogenicity of a third vaccination in previously humoral non-responding patients. METHODS: We investigated the humoral and cell-mediated immune response after SARS-CoV-2 messanger RNA vaccination in patients with a history with anti-CD20 therapies...
March 2022: RMD Open